Gain-of-function mutation of c-kit gene and molecular target therapy in GISTs

Japanese Journal of Gastroenterology

Volumn 100, Issue 1, 2003, Pages 13-20

  Hirota, Seiichi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DESMIN; IMATINIB; VIMENTIN;

ARTICLE; COILED BODY; GASTROINTESTINAL TUMOR; GENE MUTATION; GENE TARGETING; HUMAN; LEIOMYOBLASTOMA; LEIOMYOMA; NEURILEMOMA; ONCOGENE C KIT;

EID: 0037239753     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Maeda H, Yamagata A, Nishikawa S, et al: Requirement of c-kit for development of Intestinal pacemaker system. Development 1992; 116: 369-375
2. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
3. Isozaki K, Hirota S, Nakama A, et al: Disturbed intestinal movement, bile reflux to the stomach and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 1995; 109: 456-464
4. Thomsen L, Robinson TL, Lee JCF, et al: Interstitial cells of Cajal generate a rhythmic pacemaker current. Nature Med 1998; 4: 848-851
5. Furitsu T, Tsujimura T, Tono T, et al: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit. J Clin Invest 1993; 92: 1736-1744
6. Hirota S, Okazaki T, Kitamura Y, et al: Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 2000; 24: 326-327
7. Isozaki K, Terris B, Belghiti J, et al: Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000; 157: 1581-1585
8. Hirota S, Nishida T, Isozaki K, et al: Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002; 122: 1493-1499
9. Beghini A, Tibiletti MG, Roversi G, et al: Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92: 657-662
10. Chen H, Hirota S, Isozaki K, et al: Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumors. Gut 2002; 51: 793-796
11. Lux ML, Rubin BP, Biase TL, et al: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-795
12. Lasota J, Wozniak A, Sarlomo-Rikala M, et al: Mutaions in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. Am J Pathol 2000; 157: 1091-1095
13. Hirota S, Nishida T, Isozaki K, et al: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001; 193: 505-510
14. Nishida T, Hirota S, Taniguchi M, et al: Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genet 1998; 19: 323-324
15. Maeyama H, Hidaka E, Ota H, et al: Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120: 210-215
16. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566
17. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI571. a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932
18. Tuveson DA, Willis NA, Jacks T, et al: STI571 inactivation of the gastrointestinal stromal tumor c-kit oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054-5058
19. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056
20. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of Imatinib mesylate in advanced gastrointestunal stromal tumors. N Engl J Med 2002; 347: 472-480
21. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imanitib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423